Li Kang Biomedical Co Ltd

Li Kang Biomedical Co Ltd has a market price of 38.3 TWD per share and a market capitalization of 1,218,208,100 TWD. The company's price-to-earnings ratio is 97.39, which is significantly higher than the typical valuation for the food processing industry, indicating a premium valuation relative to earnings. The price-to-book ratio is 1.4, and the price-to-tangible-book ratio is also 1.4, suggesting that the company's market value is slightly above its book value. The enterprise value to EBITDA ratio is 92.50, and the enterprise value to revenue ratio is 10.62, both of which are elevated compared to industry norms.

The company's profitability metrics show a return on equity of 1.44% and a return on assets of 1.17%, which are below the industry median for food processing companies. The operating margin is 11.48%, and the net profit margin is 1.01%, indicating that the company is generating relatively low returns on its operations. The gross profit margin is 68.46%, which is in line with the industry average.

Li Kang Biomedical Co Ltd's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue for the latest period is 123,259,000 TWD, and there is no information available on the geographic distribution of this revenue. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.1, indicating that the company is primarily financed through equity.

The company's growth trajectory is not clearly defined, as there is no information available on the expected revenue growth for the current or next fiscal year. The company's operating cash flow is 10,600,000 TWD, and its free cash flow is 13,200,000 TWD, indicating that the company is generating positive cash flow from operations. The capital expenditure for the latest period is -2,811,000 TWD, suggesting that the company is not investing heavily in new assets.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is that the company has negative net cash after subtracting total debt, which could impact its ability to meet short-term obligations. The company's liquidity position is supported by a current ratio of 5.28, indicating that it has sufficient current assets to cover its current liabilities.

There are no recent events or filings disclosed that would significantly impact the company's operations or financial position. The company's financial statements do not indicate any material changes in its business strategy or operations in the latest reporting period.

Li Kang Biomedical achieved an 11.1% revenue CAGR over four years, demonstrating consistent top-line growth momentum.

Operating margin of 11.48% is double the Food Processing cohort median, indicating superior operational efficiency.

Net income grew at a 13.0% CAGR over four years, outpacing revenue growth significantly.

The debt-to-equity ratio of 0.1 is well below the cohort median of 0.32, suggesting low leverage risk.

Return on equity of 1.44% falls significantly below the Food Processing cohort median of 4.99%.

The company faces a high credit risk flag, indicating potential difficulties in meeting financial obligations.

Return on assets of 1.17% is low, suggesting inefficient utilization of assets to generate profit.

Cash conversion ratio of 0.85 is below the cohort median of 0.98, indicating weaker cash generation quality.